Navigation Links
Cabazitaxel with radiation and hormone therapy may improve prostate cancer survival
Date:1/12/2012

PHILADELPHIAJefferson's Kimmel Cancer Center has started a Phase I clinical trial investigating the latest prostate cancer chemotherapy drug to extend survival, Cabazitaxel, in combination with radiation and hormone therapy. This first-of-its-kind multimodality approach could improve disease control and eventually survival for locally advanced prostate cancer patients.

The single-center, open-label, non-randomized Phase I study of weekly Cabazitaxel with concurrent intensity modulated radiation therapy (IMRT) and androgen deprivation therapy will test its safety and the tolerable maximum dosing.

Cabazitaxel was approved in the U.S. for second-line use in advanced hormone-refractory prostate cancer in men in 2010, and has been described as a major advance in chemotherapy for advanced prostate cancer. It extended overall survival by 2.4 months when compared with mitoxantrone in patients who were previously treated with docetaxel. However, a multimodality approach with the drug has never been studied.

"We know the drug is effective in prostate cancer, but there is no study with radiation and hormone therapy yet," said principal investigator Jianqing Lin, M.D., an assistant professor of medical oncology at Thomas Jefferson University Hospital. "Concurrent radiation may have a better control for localized disease, and better long-term survival for these high-risk patients."

IMRT is a type of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor; androgen deprivation therapy is a treatment to suppress or block the production or action of male hormones. Enrolled men will receive weekly treatments of the chemotherapy drug and hormone therapy and then every three months until two years after completion of IMRT.

For the clinical trial, Dr. Lin is partnering with co-investigator Timothy Showalter, M.D., an assistant professor in the Department of Radiation Oncology at Thomas Jefferson University Hospital.


'/>"/>

Contact: Steve Graff
stephen.graff@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert  

Related medicine news :

1. Experts offer pointers for optimizing radiation dose in pediatric CT
2. Breast Cancer Radiation Linked to Raised Heart Risk
3. Targeted Radiation for Breast Cancer May Be Overused: Study
4. Scientists may be able to double efficacy of radiation therapy
5. Childhood cancer survivors exposure to chemotherapy, radiation does not increase risk of birth defects in their children
6. Blue light irradiation promotes growth, increases antioxidants in lettuce seedlings
7. Radiation May Also Lead to Chemo Brain
8. Targeted Radiation May Not Be Better for Breast Cancer
9. Study finds side effects, complications, mastectomy more likely after partial breast irradiation
10. Cancer cells DNA repair disrupted to increase radiation sensitivity
11. Dana-Farber/Childrens Hospital Boston study identifies possible therapy for radiation sickness
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cabazitaxel with radiation and hormone therapy may improve prostate cancer survival
(Date:4/21/2017)... CITY, Utah (PRWEB) , ... April 21, 2017 ... ... of wilderness therapy treatment for adolescents and young adults, has kicked off its ... 20th-Sunday, April 23rd. This year’s theme is “Attachment Informed Therapy for Mental ...
(Date:4/21/2017)... , ... April 21, 2017 , ... The Patient Advocacy ... Health System, with the 2017 Ruth Ravich Patient Advocacy Award in recognition ... advocates. DeVaro was honored with the award at The Beryl Institute’s annual Patient ...
(Date:4/21/2017)... ... ... Alive for Wellness is a group of clinical professionals and ... Alive team uses advanced behavioral sciences treatment modalities to accomplish their goals. ... struggle is based on 10 modalities of treatment that include: , ...
(Date:4/21/2017)... Ramon, CA (PRWEB) , ... April 21, 2017 , ... ... might not understand the estate planning process, or where to even begin. “Now more ... unresolved if you are to properly protect yourself and your family,” said attorney Lisa ...
(Date:4/21/2017)... ... , ... During April 21-23, Super-Sod will join the vendor market of the ... everyone — from the avid gardener to the landscape admirer — during the three-day ... in a grand venue, and we are certainly looking forward to participating in this ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  Vanderbilt University Medical Center ... in Nashville , Tennesse have been ... Sphincter Stimulation for GERD (LESS GERD) trial. The EndoStim ... long-term reflux control by restoring normal function to the ... million people in the United States ...
(Date:4/19/2017)... 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... developing new treatments for cancer and other unmet ... previously announced underwritten public offering of 23,625,084 shares ... price of $2.00 per share, before deducting underwriting ... by Sorrento.  The net proceeds to Sorrento from ...
(Date:4/19/2017)...  New research provides evidence that an old drug may ... study released today that will be presented at the ... Boston , April 22 to 28, 2017. ... disease, the oral drug levodopa has long been considered the ... the disease progresses, the effects of the medication can partially ...
Breaking Medicine Technology: